Elan, Proteostasis team up for CNS drug and diagnostics development; ended
Executive Summary
Elan Corp. PLC and Proteostasis Therapeutics Inc. (focuses on maintaining protein balance) have teamed up for a five-year period to discover and develop disease-modifying small molecules and diagnostics for neurodegenerative disorders including Parkinson’s, Huntington’s, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, and other dementia-related conditions.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice